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The activating/co-stimulatory receptor NKG2D (natural-killer group 2, member D) is
expressed on the surface of all human NK, NKT, CD8+ T, and subsets of γδ+ T cells. The
significance of NKG2D function in tumor immunity has been well demonstrated in exper-
imental animal models. However, the role of human NKG2D ligands in regulating tumor
immunity and cancer prognosis had been controversial in the literature. In this review, we
summarize the latest advancement, discuss the controversies, and present evidence that
membrane-bound and soluble NKG2D ligands oppositely regulate tumor immunity.We also
discuss new perspectives of targeting NKG2D ligands for cancer immunotherapy.
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INTRODUCTION
The discovery of the natural killer (NK) cell activating recep-
tor NKG2D and its ligand MHC I chain-related molecule (MIC)
expression on human cancer cells marks one of the most signif-
icant milestones in understanding NK cells in cancer immune
surveillance in the last several decades (1–4). NKG2D, initially
identified on NK cells, was also found to be expressed by CD8
T cells (only activated CD8 T cells in mouse), NKT cells, and
subsets of γδ T cells (4–6). In vitro studies have demonstrated
that ligation of NKG2D by its ligands provides activating signal
to NK cells and co-stimulatory signal to T cells (5, 7, 8). In vivo
studies with experimental animals have demonstrated that ectopic
expression of NKG2D ligands on tumor cells is sufficient to cause
tumor rejection (9, 10). These data suggested that sustaining or
increasing NKG2D expression on tumor cells should be a viable
avenue for developing effective cancer immunotherapy. However,
human cancer cells are found to broadly express NKG2D ligands
and yet progress (1, 11). Moreover, clinical studies with differ-
ent cancer types and even different disease stages within the same
type of cancer presented conflicting prognostic values of NKG2D
ligands (12–15). The conundrum and controversy have with-
held the further exploration of NKG2D ligand-mediated cancer
immunotherapy. In this review, we will analyze controversial clin-
ical studies and consolidates the discrepancy in the literature. We
will present most updated evidence that different physical forms
of NKG2D ligands could oppositely regulate tumor immunity.
We also propose therapeutic perspectives and options for exploit-
ing NKG2D ligands-based cancer immunotherapy. Finally, we will
also introduce a newly developed pre-clinical “humanized” mouse
model for validating immunotherapies to target NKG2D ligands.
NKG2D, AN ACTIVATING IMMUNE RECEPTOR
Natural-killer group 2, member D, also known as Klrk1 (NKG2D),
a C-type lectin-like receptor, was firstly identified in natural killer
(NK) as an activating immune receptor (16). In human, NKG2D
is not only expressed by all NK cells (17, 18), but is also expressed
by all CD8+ T cells, and subsets of γδ+ T cells as a co-stimulatory
receptor (2, 6, 8, 19). In mice, NKG2D is also expressed by all
NK cells, however, only by activated CD8+ T cells and approxi-
mately 25% of spleen γδ+ T cells (7). NKG2D is also expressed
by activated mouse macrophage (7). NKG2D is rarely expressed
by mouse intestinal intraepithelial γδ+ T cells (20). Little or no
CD4+ T cells naturally express NKG2D in both human and mouse.
Notably, NKG2D is not only expressed in mice and humans but
also expressed in other mammals (21, 22).
NKG2D is a type II transmembrane glycoprotein, which does
not contain any known signaling elements in the intracellu-
lar domain (23). Resembling many activating receptors, NKG2D
depends on an adaptor molecule to initiate signaling transduction
and cellular activation. Two adaptor molecules, DNAX-activating
proteins of 10 kDa (DAP10) and 12 kDa (DAP12), were identified
to associate with NKG2D. The selection of adaptor molecule asso-
ciation depends on the cell types and the isoforms of NKG2D. In
resting mouse NK cells, NKG2D exclusively associates with DAP10;
whereas in activated NK cells, NKG2D associates with DAP10 and
DAP12 (24, 25). In both human and activated mouse T cells,
NKG2D exclusively associates with DAP10, presumably due to
CD8 T cells lacking DAP12 expression (20, 23). In mice, alternative
splicing generates two NKG2D isoforms, NKG2D long (NKG2D-
L) and the alternatively spliced NKG2D short (NKG2D-S) which
is 13 amino acid shorter in the cytoplasmic N-terminus than
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NKG2D-L (25). Initial study with primary mouse NK cells demon-
strated that NKG2D-S associated with DAP10 or DAP12, whereas
NKG2D-L exclusively associated with DAP10 (25). A more recent
study found that DAP10 and DAP12 competed equally for binding
NKG2D variants when co-expressed in CD8 T cells (26). These
findings suggested that NKG2D signaling could be more com-
plicated than our current understandings. Similarly, the isoform
NKG2D-s was found initially only in activated mouse NK cells
and later was also described in naïve mouse NK cells (25). Whether
activated human NK cells and macrophages also express NKG2D is
controversial to date due to discrepancies in different experimen-
tal settings by different investigators (27, 28). DAP 10 and DAP12
association activates different signaling pathways (Figure 1). The
DAP10 molecule contains an YXXM tyrosine-based motif (23)
that recruits the p85 subunit of phosphoinositide kinase-3 (PI3K)
and growth factor receptor-bound protein 2 (Grb2). This signaling
cascade is similar to which delivered by the T cell co-stimulatory
molecules CD28 and ICOS (29, 30). The DAP12 molecule con-
tains an ITAM, which recruits ZAP70 and Syk to mediate NK cell
activation (25). The selection of adaptor molecule and the ensuing
activation of different signaling pathways may explain the func-
tional differences of NKG2D in NK cells and T cells. Binding of
NKG2D to its ligands is sufficient to induce NK cell activation,
even with inhibitory signals, such as MHC molecules (31), but
only co-stimulates CD8 T cells or γδ T cells (8, 32).
NKG2D expression and signaling can be regulated by cytokines
and tumor-derived factors. Cytokines, such as IL-2, IL-7, IL-12,
IL-15, and type I interferons (IFNs) increase cell surface expres-
sion of NKG2D (33). IL-15 signaling not only regulates NKG2D
expression but also increases the expression of DAP10 and phos-
phorylates the adaptor molecule to prime NKG2D signaling (34).
On the contrary, cytokines such as IL-21, IFN-γ, and TGF-β
have been shown to decrease NKG2D expression. IL-21 has been
reported to reduce expressions of DAP10 and NKG2D in human
CD8+ T cells and NK cells (35). In mice, IL-21 stimulation of NK
cells is dependent on regulating the NKG2D expression in mouse
model of breast carcinoma (36). TGF-β has been shown to down-
regulate NKG2D expression; however, the effect can be reversed
by IL-2 or IL-18 (37).
REGULATION OF NKG2D LIGANDS
NKG2D ligands are structural homologs of MHC class I mole-
cules. NKG2D ligands are absent or rarely expressed in normal
tissues, but are extensively expressed in various malignancies and
viral-infected tissues (8, 11). The identified human NKG2D lig-
ands include class-I-related chains-related molecules A and B
(MICA and MICB) proteins and retinoic acid early transcripts-
1 (RAET1), also known as UL-16 binding proteins (38). To date,
identified mouse NKG2D ligands include five different RAET1
isoforms (RAET1α, RAET1 β, RAET1 γ, RAET1 δ, and RAET1 ε),
three different H60 isoforms (H60a, b, and c), and one MULT1
gene (39, 40) (Figure 2). No MIC homologs have been identified
in rodents. Although NKG2D ligands are structural homologs of
MHC class I molecules, they do not present antigen to T cells or
bind β2-microglobulin (1).
NKG2D ligands are prevalently expressed in human malignan-
cies. MIC and ULBP families of ligands are found prevalently
expressed by carcinomas of the breast, lung, colon, ovary, kidney,
and prostate, melanomas, gliomas, and leukemia (2, 11, 12, 41–
43). Certain normal human tissues such as gastric and bronchial
epithelia were found to express NKG2D ligand MIC (44). Given
that NKG2D ligand expression can be induced by stress and that
gastric and bronchial mucosal epithelia are frequently exposed
to microbial organisms (1), these observations are anticipated.
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FIGURE 1 | NKG2D receptor and signaling pathways associated with
adaptor molecules. The NKG2D receptor forms a homodimer that
associates with the adaptor molecules DAP10 or DAP12. Association of
NKG2D with DAP10 initiates PI3K and Grb2–Vav–Sos1 signaling
pathways, whereas association of NKG2D with DAP12 initiates
Syk/ZAP70 signaling cascade. NKG2D-S can promiscuously associate
with DAP10 or DAP12. NKG2D-L primarily associates with DAP 10.
Whether NKG2D-L also associates with DAP12 is controversial.
NKG2D-L is expressed by all NK cells, human CD8 T cells, and activated
mouse CD8 T cells. Activated mouse NK cells and macrophages express
NKG2D-S. Whether activated human NK cells and CD8 T cells express
NKG2D-S is also controversial.
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FIGURE 2 | Schematic illustration of identified ligands for human and
mouse NKG2D. The unique human NKG2D ligands MICA and MICB have
α1, α2, and α3 extracellular domains and transmembrane domains, sharing
structural homology with MHCI. All other human NKG2D ligands and all
mouse NKG2D ligands lack the α3 domain. Murine NKG2D ligands, RAE1
α–ε and H60c, and human ULBP1-6 are glycosylphosphatidylinositol
(GPI)-linked to the membrane. Human ligands, ULBP4 and ULBP5, and
mouse ligands, MULT1, and H60a and H60b, are transmembrane proteins.
The gut epithelium constitutively expresses MICA; however, the
expression can be altered with changes in the gut flora in inflam-
matory states such as Crohn’s disease and celiac disease (45, 46). Of
note, NKG2D ligands are also found to be upregulated in activated
T cells of both human and mouse origin (47, 48). Collectively, these
studies suggest that NKG2D ligand expression in tissues is regu-
lated by the pathogenic physiological environment to adequately
differentiate between healthy and potential target cells.
Regulation of NKG2D ligand exerts at different levels, including
transcription, mRNA stability, translation, protein stabilization,
and excretion/shedding of ligands from cells (40, 49–51). DNA
damage response induces the transcription of an array of NKG2D
ligands, such as ULBP1 and ULBP2 and MIC family molecules
(52). Regulation of NKG2D ligands in response to DNA damage
depends on the accumulation of cytosolic DNA and the induction
of nucleotide sensing pathways, which activate the TANK-binding
kinase 1 and the IFN regulatory factor 3 (53). In addition, MICA,
MICB, and ULBP3 transcripts have been reported to be targeted
by endogenous microRNAs (54). Inhibition of PI3K impaired
Raet1 transcript levels, and was further observed at the protein
level suggesting that PI3K regulates Raet1 at the transcriptional
and post-transcriptional stage (55). In addition to its role in
transcriptional regulation of MICA and MICB (56), heat shock
counteracts ubiquitin-mediated degradation of MULT1 (57). At
the post-translational level, NKG2D ligands such MICA, MICB,
and ULBPs were found to be cleaved from the cell surface by
proteases ADAM10/17 and MMP14 and in some cases by tumor-
derived exosomes (58–62). Notably, expression of NKG2D ligands
was also shown to be downregulated by cytokines such as IFN-
γ, IFN-α, transforming growth factor-β, and IL-10, although the
underlying mechanisms have not been elucidated extensively (63).
TWO FACES OF NKG2D LIGANDS IN REGULATING TUMOR
IMMUNITY
Although induction of NKG2D ligand expression is associated
with oncogenesis, expression of NKG2D ligands does not favor
progression to carcinoma. In fact, multiple lines of evidence
conclusively demonstrated that NKG2D ligand-induced recep-
tor activation plays a significant role in tumor immune surveil-
lance. Ectopic expression of NKG2D ligands on diverse tumor
cell lines resulted in tumor rejection in experimental animal
models through activation of NK cells and in some cases CD8
T cells (7, 9, 10, 52). To support the significance of ligand-
engaged NKG2D function in tumor inhibition, an elegant study
by Smyth et al. demonstrated that antibody neutralizing NKG2D
increased the incidence of MCA-induced sarcoma formation (64).
Furthermore, Guerra et al. using a genetic approach showed
that NKG2D-deficient transgenic adenocarcinoma of the mouse
prostate (TRAMP) developed three times more aggressive tumors
than NKG2D-intact TRAMP littermates (65). Together, these stud-
ies in experimental animal models demonstrated that immunity
mediated by ligand–NKG2D interaction plays a significant role in
controlling tumor initiation and tumor progression.
In contrast to the conclusive data from animal models, clin-
ical data eliciting the significance of NKG2D ligands in tumor
immunity are rather controversial and presented discrepancies in
conclusion. In early stages of breast and colorectal cancer, levels
of tissue MIC expression were shown to positively correlate with
improved survival (12, 15). In invasive breast and ovarian cancer,
levels of tissue MIC expression were shown to correlate with poor
prognoses (13,14). These conflicting clinical observations are most
likely resulted from discrepancies on how the ligand expression
is assayed. Human cancer cells have broadly adapted a proteases
or exosome-mediated strategy to shed surface NKG2D ligands
(51). It has been proposed that membrane-bound NKG2D lig-
ands stimulate immunity whereas soluble NKG2D ligands impair
host immunity. The concept that membrane-bound and soluble
forms of NKG2D ligands oppositely regulate tumor immunity was
recently demonstrated by two elegant lines of “humanized” trans-
genic animals. Liu et al. created two lines of transgenic animals that
express native human MICB and engineered shedding-resistant
mutant MICB (MICB.A2) specifically in the mouse prostate under
the control of prostate-specific promoter. These two lines of trans-
genic animals have no differences phenotypically. However, when
they were crossed with the TRAMP mice that develop spon-
taneous prostate tumors, TRAMP/MICB mice exhibited expe-
dited tumor progression in comparison to TRAMP littermates
whereas TRAMP/MICB.A2 mice enjoyed tumor-free survival (66).
Liu et al. further demonstrated that the tumor progression in
TRAMP/MICB mice was due to elevated serum sMIC and severe
impaired of host immunity, exemplified by depletion of peripheral
NK cell populations. This study provided the first and strongest
in vivo evidence that membrane-bound NKG2D ligands and solu-
ble NKG2D ligands play opposite roles in tumor immunity. Given
that tumor cells express more proteases as disease progression
and that elevated levels of serum sMIC correlates with invasive
malignancies in many types of cancers (66, 67–71), the conun-
drum of different clinical observation may not be “conflicting”
after all if the assay can distinguish tissue levels of sMIC versus
membrane-bound MIC.
Soluble NKG2D ligands suppress tumor immunity via multiple
mechanisms. Downregulation of NKG2D expression on effector
cells by soluble NKG2D ligands is the most common mechanism
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described thus far (2, 7, 9, 10, 64–66). Hanaoka et al. described that
sMIC can also induce loss of the CD3ζ signaling adaptor, which
occurs in T cells and NK cells in cancer patients, after NKG2D
signaling leads to Fas-mediated caspases 3/7 activation and cleav-
age of CD3ζ (72), leading to T cell and NK cell dysfunction. Liu
et al. have recently described that sMIC impairs the ability of NK
cells to self-renew in tumor host and thus perturbs NK cell home-
ostasis (66). Given that NK cells play a significant role in shaping
adaptive immunity by providing IFNγ and priming dendritic cells,
the magnitude of negative imprints of sMIC on tumor immunity
may be larger than we have understood. Nonetheless, these stud-
ies imply the critical role of NKG2D ligands in regulating tumor
immunity although the mechanism may be a complex.
TARGETING NKG2D LIGANDS FOR CANCER IMMUNITY
The significance of NKG2D-mediated immunity in controlling
tumor development and progression has been well demonstrated.
It is also evident that different membrane-bound and solu-
ble NKG2D ligands oppositely regulate NKG2D-mediated tumor
immunity. Based on these understandings, cancer therapeutic
interventions should be focused on at least the following aspects:
(a) sustain and enhance NKG2D expression and signaling on effec-
tor cells; (b) sustain and enhance the level of membrane-bound
NKG2D ligand on tumor cells; (c) eliminate soluble NKG2D
ligands.
Tumor-derived sMIC has been shown to not only downregu-
late NKG2D expression on effector cells but also to perturb NK cell
peripheral maintenance. One candidate strategy to overcome or
reduce the negative effect of sMIC on effector cells is through inter-
vention of IL-15 agonists. As a member of the gamma cytokine
family, IL-15 can not only increase NKG2D expression (10, 73–
75) but also cross-prime NKG2D signaling pathways (34). We
have shown that IL-15 can restore and further augment NKG2D
expression on NK cells isolated from cancer patients that have
lost surface NKG2D expression (76, 77). Moreover, IL-15 has been
shown to be important for NK cell homeostatic maintenance (78,
79) (Figure 3A). With IL-15 or its agonist currently in clinical
trial, this therapy alone or in combination with strategies targeting
sMIC is soundly plausible.
With the understanding of how shedding of MIC is regu-
lated in tumor cells (49, 51), several therapeutic targets may
be considered. Proteases, such as ADAM (a disintegrin and
metalloproteinase)-10, ADAM-17 (60), and MMP-14 have been
found to directly contribute to MIC shedding through prote-
olytic activities (62, 80). The thiol isomerase ERp5 has been
shown to regulate MIC shedding by reducing the disulfide bond
of MIC to induce conformational changes and thus allow the
access of proteolytic enzymes (81). Theoretically, ERp5 and the
MIC-shedding-contributing proteases should be considered as
therapeutic targets. However, given the broad and constitutive
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FIGURE 3 | Potential therapeutic interventions to target NKG2D ligand
MIC for cancer immunotherapies. (A) Counteracting the negative effect of
soluble MIC on the receptor and NK cells with IL-15 agonists. Signaling
initiated by IL-15 agonists not only results in JAK3-mediated activation of
STAT5 and PI3K pathways to support NK cell proliferation and survival but also
phosphorylates the adaptor DAP10 to prime NKG2D signaling. (B) Antibody or
small molecule to block the interaction of MIC with ERp5 and thus inhibits
MIC shedding. (C) Therapy with MIC specific antibody to: (i) neutralize serum
sMIC and thus revive NK cell homeostasis and augment CD8 T cell function;
(ii) opsonize tumor cells to enhance DC endocytosis through Fc receptor and
cross-presentation of tumor antigen to effector T cells; (iii) induce
antibody-dependent cytotoxicity of NK cells.
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function of these molecules in normal cellular physiology, ther-
apeutic targeting could be challenging to avoid systemic toxi-
city. However, a highly conserved six-amino acid (6-aa) motif
in the α3 domain of MIC has been identified to regulate the
interaction of MIC with ERp5 and thus the shedding of MIC
(82). Mutation of the six-amino acid motif completely prevented
MIC shedding and enhanced tumor cell susceptibility to NK cell
killing (82). Given the restricted expression of MIC, targeting the
MIC-shedding regulatory motif may be more feasible for thera-
peutic intervention to sustain tumor cell surface MIC expression
(Figure 3B).
One of the promising strategies to overcome immune suppres-
sive effect of sNKG2D ligands is neutralizing antibody (Figure 3C).
The idea is supported by clinical observations demonstrating
that patients who developed anti-MIC autoantibody had reduced
serum sMIC and better prognosis (83). In a clinical trial of
melanoma patients with anti-CTLA-4 antibody blockade vaccine
with autologous tumor cells engineered to express GM-CSF, it was
shown that patients with high level of anti-MICA autoantibody
presented better response to therapy (84). At least three mech-
anisms could contribute to the enhanced therapeutic responses.
The first would be the evident reduction of serum sMIC to
eliminate its immune suppressive effect. The second is through
antibody opsonizing antigen presenting DC cells to enhance cross-
presentation of tumor cells that express membrane-bound MIC
(84, 85). The third may be through antibody-mediated ADCC
effect to enhance NK cell killing of tumor cells that express
membrane-bound MIC.
As a final reminder, the efficacy of targeting MIC-shedding
motif or of an antibody directly targeting sMIC as novel inter-
vention for cancer immunotherapy needs to be validated in pre-
clinical models before moving to clinical trials. Due to the limi-
tation that no human MIC homology is identified in rodents and
that tumor shedding of MIC is only described in cancer patients,
no clinically relevant animal model has been available to vali-
date these therapeutic interventions until the recently described
TRAMP/MIC double transgenic mouse model (66). Liu et al.
described that the TRAMP/MIC mice closely resemble a broad
spectrum of MIC+ cancer patients in the dynamic interaction of
MIC-shedding and cancer progression. This model should provide
a very useful tool for pre-clinical validation of targeting NKG2D
ligand MIC for cancer immunotherapy.
CONCLUSION
In summary, it is evident that NKG2D-mediated immunity is sig-
nificant in potentiating anti-tumor responses. The exploitation of
the NKG2D/NKG2D ligands pathway could be a promising strat-
egy for anti-tumor immune therapy. However, NKG2D ligands
present two contradictory faces in regulating NKG2D-mediated
anti-tumor immunity. Membrane-bound NKG2D ligands stimu-
late anti-tumor immunity whereas soluble ligands suppress anti-
tumor immunity. Based on these understandings, interventions
for cancer immunotherapy should aim at enhancing NKG2D
expression and signaling in effector cells, sustaining the highest
levels of NKG2D ligands on tumor cell surface, and eliminat-
ing soluble NKG2D ligands. The recently developed “human-
ized” TRAMP/MIC mice should serve as a powerful tool for
validating various targeting strategies for MIC+ malignancies,
which represents the majority of human cancers.
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